Take On Cancer is what we do at the University of Michigan Comprehensive Cancer Center. In a world where 1 in 2.5 people will hear "it's cancer," we want to make sure that you are able to take on cancer too.
Knowledge is everything - stay engaged, informed and prepared.
The average metastatic cancer has more genetic mutations than are seen in early stage tumors, a new study finds. What that means: To make precision medicine a reality in cancer care, you need a real-time, comprehensive approach that looks at the metastatic tumors and sequences to a level of detail beyond most commercial tests.
In a new perspective piece published in the New England Journal of Medicine, University of Michigan Comprehensive Cancer Center researchers look at whether active surveillance could be a strategy to reduce overtreatment in certain patients.
In a new study, gene therapy deployed with immune checkpoint inhibitors demonstrates potential benefit for devastating brain cancer. That's how leading researchers describe the present outlook for malignant brain tumors. The median survival rate for patients with glioblastoma multiforme, or GBM, is a mere 14.2 months.
Researchers studied prostate cancer patients with multiple cancer diagnoses, many who would not be recommended for genetic tests following current guidelines, to identify genetic mutations that may influence cancer treatment and cancer risk assessment for family members. Their findings are reported in the June issue of the journal Cancer.
Researchers at the University of Michigan will lead one of five nationally funded centers dedicated to accelerating research into understanding the molecular basis of cancer and sharing resources with the scientific community.
Alexey Nesvizhskii and colleague at a computer in the labU-M researchers received a grant from the National Cancer Institute to establish a Proteogenomic Data Analysis Center. The center will comprehensively characterize cancer tumor samples to integrate and analyze proteogenomic data to improve researchers’ ability to develop more targeted cancer therapies.
In a dramatic shift since the publication of margin guidelines for breast cancer surgery, lumpectomy rates have substantially increased and more-aggressive surgical options have been used less often, according to research findings from a new study presented at the 2017 annual meeting of the American Society of Clinical Oncology in Chicago. The study will also be published in a corresponding issue of JAMA Oncology.
As thyroid cancer rates rise, more people are having surgery to remove all or part of their thyroid. A new study suggests complications from these procedures are more common than previously believed.
To understand what makes breast cancer spread, researchers are looking at where it lives -- not just its original home in the breast but its new home where it settles in other organs. What's happening in that metastatic niche where migrated cancer cells are growing?
Even as treatment options for laryngeal cancer seemed to improve, survival rates did not. For the most advanced patients, 50 percent survival was the norm, whether patients had surgery to remove the voice box or alternative treatment with chemotherapy and radiation to try to avoid surgery.
Nearly one-third of early stage breast cancer patients overestimate their risk of cancer recurrence -- believing it to be more than double their actual risk. And that overestimation is affecting their quality of life, according to two recent studies. The good news? A more nuanced approach to doctor-patient communication may help improve patients’ understanding.
While it might be expected for women undergoing chemotherapy, researchers found one-third of women who didn’t receive chemotherapy experienced severe side effects of treatment as well. Overall, side effects led to additional doctor’s appointments, trips to the emergency room, delays in treatment and reduced dosages.
PDX1, a transcription factor critical for pancreatic development, has distinct roles at different stages of pancreatic cancer: keeping cancer at bay in normal cells, then eventually contributing to the cancer's growth once a tumor forms and also preventing the tumor from becoming more aggressive.
In January 2016, President Barack Obama announced a "Cancer Moonshot" to achieve a decade's worth of progress in cancer prevention, diagnosis and treatment in five years.
For more articles on cancer research progress, please visit our News Archive.